Literature DB >> 26667246

Bisphosphonate drug holidays: we reap what we sow.

S L Silverman1, J D Adachi2, E Dennison3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26667246     DOI： 10.1007/s00198-015-3453-y

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  21 in total

1.  Bisphosphonates for osteoporosis--where do we go from here?

Authors:  Marcea Whitaker; Jia Guo; Theresa Kehoe; George Benson
Journal:  N Engl J Med       Date:  2012-05-09       Impact factor: 91.245

2.  Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.

Authors:  Douglas C Bauer; Ann Schwartz; Lisa Palermo; Jane Cauley; Marc Hochberg; Art Santora; Steven R Cummings; Dennis M Black
Journal:  JAMA Intern Med       Date:  2014-07       Impact factor: 21.873

3.  Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study.

Authors:  P N Sambrook; I D Cameron; J S Chen; L M March; J M Simpson; R G Cumming; M J Seibel
Journal:  Osteoporos Int       Date:  2010-10-20       Impact factor: 4.507

Review 4.  Bone safety of long-term bisphosphonate treatment.

Authors:  Gideon Rodan; Alfred Reszka; Ellis Golub; René Rizzoli
Journal:  Curr Med Res Opin       Date:  2004-08       Impact factor: 2.580

Review 5.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

6.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

Review 7.  Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).

Authors:  E Hernlund; A Svedbom; M Ivergård; J Compston; C Cooper; J Stenmark; E V McCloskey; B Jönsson; J A Kanis
Journal:  Arch Osteoporos       Date:  2013-10-11       Impact factor: 2.617

8.  The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

9.  Risk of atypical femoral fracture during and after bisphosphonate use.

Authors:  Jörg Schilcher; Veronika Koeppen; Per Aspenberg; Karl Michaëlsson
Journal:  Acta Orthop       Date:  2015-01-13       Impact factor: 3.717

10.  Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?

Authors:  Felicia Cosman; Jane A Cauley; Richard Eastell; Steven Boonen; Lisa Palermo; Ian R Reid; Steven R Cummings; Dennis M Black
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958
View more
  2 in total

1.  Fracture risk following intermission of osteoporosis therapy.

Authors:  E M Dennison; C Cooper; J A Kanis; O Bruyère; S Silverman; E McCloskey; B Abrahamsen; D Prieto-Alhambra; S Ferrari
Journal:  Osteoporos Int       Date:  2019-06-07       Impact factor: 4.507

2.  Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.

Authors:  M A Mignot; N Taisne; I Legroux; B Cortet; J Paccou
Journal:  Osteoporos Int       Date:  2017-09-05       Impact factor: 4.507
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.